A Phase III clinical trial of cadonilimab combined with a VEGFR-2 monoclonal antibody for PD-1/L1 inhibitor-pretreated advanced gastric adenocarcinoma and gastroesophageal junction adenocarcinoma ...

Treating initially unresectable gastric or GEJ cancer with camrelizumab plus nab-POF led to an R0 resection rate of 75% in a phase 2 trial.

Conversion therapy has become a hot topic among specialists in gastrointestinal cancers, said Pamela Kunz, MD, of the Yale ...

The phase 3 CheckMate 649 trial showed that nivolumab plus chemotherapy significantly improved long-term overall survival in ...

(B) Surgically resected gastric adenocarcinoma. A positive case for any percentage of TC with 2+ to 3+ intensity membranous staining. (C) Liver core-needle biopsies, metastatic gastric adenocarcinoma.

Opdivo plus chemo showed long-term survival advantages in Chinese patients with advanced gastric, gastroesophageal junction ...

Role of intraperitoneal paclitaxel in eosinophil activation and recruitment in the peritoneal cavity and anti-tumor effects against peritoneal metastasis from gastric cancer. This is an ASCO Meeting ...

Among patients with advanced gastric and GEJ cancer, or esophageal adenocarcinoma, treatment with first-line Opdivo and chemo demonstrated deep responses.

CheckMate 649 trial showed sustained efficacy with frontline nivolumab plus chemotherapy vs chemotherapy alone in patients with gastric cancers.

The FDA expanded the approval of trastuzumab deruxtecan for treatment of breast cancer.The new indication applies to use of ...